nodes	percent_of_prediction	percent_of_DWPC	metapath
Erlotinib—kidney cancer—muscle cancer	0.313	0.509	CtDrD
Erlotinib—lung cancer—muscle cancer	0.302	0.491	CtDrD
Erlotinib—CYP1A1—Dacarbazine—muscle cancer	0.029	0.115	CbGbCtD
Erlotinib—UGT1A1—Etoposide—muscle cancer	0.0279	0.11	CbGbCtD
Erlotinib—ABCG2—Dactinomycin—muscle cancer	0.0272	0.108	CbGbCtD
Erlotinib—CYP1B1—Doxorubicin—muscle cancer	0.022	0.0872	CbGbCtD
Erlotinib—ABCG2—Vincristine—muscle cancer	0.0168	0.0663	CbGbCtD
Erlotinib—ABCG2—Etoposide—muscle cancer	0.0154	0.0608	CbGbCtD
Erlotinib—CYP1A2—Dacarbazine—muscle cancer	0.0129	0.0512	CbGbCtD
Erlotinib—ABCG2—Doxorubicin—muscle cancer	0.0105	0.0414	CbGbCtD
Erlotinib—ABCG2—Methotrexate—muscle cancer	0.0102	0.0401	CbGbCtD
Erlotinib—ABCB1—Dactinomycin—muscle cancer	0.00982	0.0388	CbGbCtD
Erlotinib—CYP3A5—Vincristine—muscle cancer	0.00929	0.0367	CbGbCtD
Erlotinib—CYP3A5—Etoposide—muscle cancer	0.00851	0.0337	CbGbCtD
Erlotinib—CYP2C8—Etoposide—muscle cancer	0.00818	0.0324	CbGbCtD
Erlotinib—ALB—Methotrexate—muscle cancer	0.007	0.0277	CbGbCtD
Erlotinib—CYP1A2—Etoposide—muscle cancer	0.00634	0.0251	CbGbCtD
Erlotinib—ABCB1—Vincristine—muscle cancer	0.00605	0.0239	CbGbCtD
Erlotinib—ABCB1—Etoposide—muscle cancer	0.00554	0.0219	CbGbCtD
Erlotinib—ABCB1—Doxorubicin—muscle cancer	0.00378	0.0149	CbGbCtD
Erlotinib—ABCB1—Methotrexate—muscle cancer	0.00366	0.0145	CbGbCtD
Erlotinib—CYP3A4—Vincristine—muscle cancer	0.00362	0.0143	CbGbCtD
Erlotinib—CYP2D6—Doxorubicin—muscle cancer	0.00356	0.0141	CbGbCtD
Erlotinib—CYP3A4—Etoposide—muscle cancer	0.00332	0.0131	CbGbCtD
Erlotinib—CYP3A4—Doxorubicin—muscle cancer	0.00226	0.00895	CbGbCtD
Erlotinib—Vandetanib—VEGFA—muscle cancer	0.00147	1	CrCbGaD
Erlotinib—AURKC—tendon—muscle cancer	0.00078	0.0214	CbGeAlD
Erlotinib—LTK—head—muscle cancer	0.000775	0.0213	CbGeAlD
Erlotinib—NR1I2—head—muscle cancer	0.000775	0.0213	CbGeAlD
Erlotinib—HIPK4—testis—muscle cancer	0.000757	0.0208	CbGeAlD
Erlotinib—LTK—testis—muscle cancer	0.000749	0.0206	CbGeAlD
Erlotinib—AURKC—head—muscle cancer	0.000669	0.0184	CbGeAlD
Erlotinib—TNK1—tendon—muscle cancer	0.000664	0.0182	CbGeAlD
Erlotinib—AURKC—testis—muscle cancer	0.000646	0.0177	CbGeAlD
Erlotinib—JAK3—head—muscle cancer	0.00062	0.017	CbGeAlD
Erlotinib—EPHA6—head—muscle cancer	0.00062	0.017	CbGeAlD
Erlotinib—TNK1—vagina—muscle cancer	0.000616	0.0169	CbGeAlD
Erlotinib—EPHA6—testis—muscle cancer	0.000598	0.0164	CbGeAlD
Erlotinib—JAK3—testis—muscle cancer	0.000598	0.0164	CbGeAlD
Erlotinib—PIP4K2C—cardiac atrium—muscle cancer	0.000591	0.0162	CbGeAlD
Erlotinib—ULK3—cardiac atrium—muscle cancer	0.000564	0.0155	CbGeAlD
Erlotinib—MAP3K19—head—muscle cancer	0.000563	0.0155	CbGeAlD
Erlotinib—FLT3—bone marrow—muscle cancer	0.000552	0.0152	CbGeAlD
Erlotinib—TNK1—testis—muscle cancer	0.000549	0.0151	CbGeAlD
Erlotinib—ABL2—tendon—muscle cancer	0.000544	0.0149	CbGeAlD
Erlotinib—MAP3K19—testis—muscle cancer	0.000544	0.0149	CbGeAlD
Erlotinib—MKNK1—cardiac atrium—muscle cancer	0.000531	0.0146	CbGeAlD
Erlotinib—ABL1—Epirubicin—Doxorubicin—muscle cancer	0.000517	0.333	CbGdCrCtD
Erlotinib—ABL1—Idarubicin—Doxorubicin—muscle cancer	0.000517	0.333	CbGdCrCtD
Erlotinib—ABL1—Daunorubicin—Doxorubicin—muscle cancer	0.000517	0.333	CbGdCrCtD
Erlotinib—PIP4K2C—tendon—muscle cancer	0.000515	0.0141	CbGeAlD
Erlotinib—ABL2—vagina—muscle cancer	0.000505	0.0139	CbGeAlD
Erlotinib—SLK—cardiac atrium—muscle cancer	0.000503	0.0138	CbGeAlD
Erlotinib—PIP4K2C—bone marrow—muscle cancer	0.000499	0.0137	CbGeAlD
Erlotinib—ULK3—tendon—muscle cancer	0.000492	0.0135	CbGeAlD
Erlotinib—STK10—renal system—muscle cancer	0.000488	0.0134	CbGeAlD
Erlotinib—PIP4K2C—vagina—muscle cancer	0.000478	0.0131	CbGeAlD
Erlotinib—ULK3—bone marrow—muscle cancer	0.000476	0.0131	CbGeAlD
Erlotinib—FLT3—testis—muscle cancer	0.000472	0.013	CbGeAlD
Erlotinib—UGT1A1—renal system—muscle cancer	0.000461	0.0127	CbGeAlD
Erlotinib—ULK3—vagina—muscle cancer	0.000456	0.0125	CbGeAlD
Erlotinib—ABL2—testis—muscle cancer	0.000451	0.0124	CbGeAlD
Erlotinib—MKNK1—bone marrow—muscle cancer	0.000448	0.0123	CbGeAlD
Erlotinib—ABL1—embryo—muscle cancer	0.000444	0.0122	CbGeAlD
Erlotinib—PIP4K2C—head—muscle cancer	0.000441	0.0121	CbGeAlD
Erlotinib—EGFR—testis—muscle cancer	0.00044	0.0121	CbGeAlD
Erlotinib—SLK—tendon—muscle cancer	0.000438	0.012	CbGeAlD
Erlotinib—MKNK1—vagina—muscle cancer	0.000429	0.0118	CbGeAlD
Erlotinib—PIP4K2C—testis—muscle cancer	0.000426	0.0117	CbGeAlD
Erlotinib—SLK—bone marrow—muscle cancer	0.000425	0.0117	CbGeAlD
Erlotinib—ULK3—head—muscle cancer	0.000422	0.0116	CbGeAlD
Erlotinib—ULK3—testis—muscle cancer	0.000407	0.0112	CbGeAlD
Erlotinib—SLK—vagina—muscle cancer	0.000407	0.0112	CbGeAlD
Erlotinib—MKNK1—head—muscle cancer	0.000397	0.0109	CbGeAlD
Erlotinib—MAP2K5—cardiac atrium—muscle cancer	0.00039	0.0107	CbGeAlD
Erlotinib—MKNK1—testis—muscle cancer	0.000383	0.0105	CbGeAlD
Erlotinib—STK10—tendon—muscle cancer	0.000381	0.0105	CbGeAlD
Erlotinib—STK10—bone marrow—muscle cancer	0.000369	0.0101	CbGeAlD
Erlotinib—SLK—testis—muscle cancer	0.000363	0.00997	CbGeAlD
Erlotinib—STK10—vagina—muscle cancer	0.000354	0.00971	CbGeAlD
Erlotinib—ABL1—smooth muscle tissue—muscle cancer	0.000349	0.00959	CbGeAlD
Erlotinib—MAP2K5—tendon—muscle cancer	0.00034	0.00935	CbGeAlD
Erlotinib—SLCO2B1—renal system—muscle cancer	0.000339	0.00932	CbGeAlD
Erlotinib—ABL1—renal system—muscle cancer	0.000336	0.00924	CbGeAlD
Erlotinib—STK10—head—muscle cancer	0.000327	0.00897	CbGeAlD
Erlotinib—MAP2K5—vagina—muscle cancer	0.000316	0.00867	CbGeAlD
Erlotinib—STK10—testis—muscle cancer	0.000316	0.00867	CbGeAlD
Erlotinib—ABL1—cardiac atrium—muscle cancer	0.000301	0.00827	CbGeAlD
Erlotinib—CYP1B1—smooth muscle tissue—muscle cancer	0.000296	0.00813	CbGeAlD
Erlotinib—MAP2K5—head—muscle cancer	0.000292	0.00801	CbGeAlD
Erlotinib—CYP1B1—renal system—muscle cancer	0.000285	0.00782	CbGeAlD
Erlotinib—MAP2K5—testis—muscle cancer	0.000282	0.00774	CbGeAlD
Erlotinib—ORM1—bone marrow—muscle cancer	0.000268	0.00735	CbGeAlD
Erlotinib—SLCO2B1—tendon—muscle cancer	0.000265	0.00727	CbGeAlD
Erlotinib—ABL1—tendon—muscle cancer	0.000263	0.00721	CbGeAlD
Erlotinib—ABL1—bone marrow—muscle cancer	0.000254	0.00698	CbGeAlD
Erlotinib—ABL1—vagina—muscle cancer	0.000244	0.00669	CbGeAlD
Erlotinib—SLCO2B1—head—muscle cancer	0.000227	0.00623	CbGeAlD
Erlotinib—ABL1—head—muscle cancer	0.000225	0.00618	CbGeAlD
Erlotinib—CYP1B1—tendon—muscle cancer	0.000222	0.00611	CbGeAlD
Erlotinib—SLCO2B1—testis—muscle cancer	0.000219	0.00602	CbGeAlD
Erlotinib—CYP2C8—renal system—muscle cancer	0.000218	0.00599	CbGeAlD
Erlotinib—ABL1—testis—muscle cancer	0.000217	0.00597	CbGeAlD
Erlotinib—Inflammation—Methotrexate—muscle cancer	0.000206	0.00351	CcSEcCtD
Erlotinib—CYP1A2—renal system—muscle cancer	0.000204	0.00561	CbGeAlD
Erlotinib—Alopecia—Dactinomycin—muscle cancer	0.000204	0.00349	CcSEcCtD
Erlotinib—Urinary tract disorder—Vincristine—muscle cancer	0.000204	0.00348	CcSEcCtD
Erlotinib—Connective tissue disorder—Vincristine—muscle cancer	0.000203	0.00346	CcSEcCtD
Erlotinib—Urethral disorder—Vincristine—muscle cancer	0.000202	0.00346	CcSEcCtD
Erlotinib—CYP1A1—renal system—muscle cancer	0.000201	0.00553	CbGeAlD
Erlotinib—Erythema—Dactinomycin—muscle cancer	0.000201	0.00344	CcSEcCtD
Erlotinib—ALB—testis—muscle cancer	0.000201	0.00551	CbGeAlD
Erlotinib—CYP3A5—renal system—muscle cancer	0.000197	0.00541	CbGeAlD
Erlotinib—Cardiovascular disorder—Doxorubicin—muscle cancer	0.000196	0.00336	CcSEcCtD
Erlotinib—Neutropenia—Etoposide—muscle cancer	0.000195	0.00334	CcSEcCtD
Erlotinib—Melaena—Methotrexate—muscle cancer	0.000195	0.00333	CcSEcCtD
Erlotinib—CYP1B1—head—muscle cancer	0.000191	0.00523	CbGeAlD
Erlotinib—Skin exfoliation—Methotrexate—muscle cancer	0.00019	0.00325	CcSEcCtD
Erlotinib—Cellulitis—Doxorubicin—muscle cancer	0.00019	0.00324	CcSEcCtD
Erlotinib—Pneumonia—Etoposide—muscle cancer	0.000187	0.0032	CcSEcCtD
Erlotinib—Infestation—Etoposide—muscle cancer	0.000186	0.00318	CcSEcCtD
Erlotinib—Infestation NOS—Etoposide—muscle cancer	0.000186	0.00318	CcSEcCtD
Erlotinib—Mediastinal disorder—Vincristine—muscle cancer	0.000186	0.00318	CcSEcCtD
Erlotinib—Stevens-Johnson syndrome—Etoposide—muscle cancer	0.000185	0.00315	CcSEcCtD
Erlotinib—CYP1B1—testis—muscle cancer	0.000184	0.00506	CbGeAlD
Erlotinib—Acute coronary syndrome—Etoposide—muscle cancer	0.000184	0.00314	CcSEcCtD
Erlotinib—Renal failure—Etoposide—muscle cancer	0.000183	0.00313	CcSEcCtD
Erlotinib—Neuropathy peripheral—Etoposide—muscle cancer	0.000182	0.00312	CcSEcCtD
Erlotinib—Myocardial infarction—Etoposide—muscle cancer	0.000182	0.00312	CcSEcCtD
Erlotinib—Alopecia—Vincristine—muscle cancer	0.000182	0.00312	CcSEcCtD
Erlotinib—Stomatitis—Etoposide—muscle cancer	0.000181	0.0031	CcSEcCtD
Erlotinib—Mental disorder—Vincristine—muscle cancer	0.000181	0.00309	CcSEcCtD
Erlotinib—CYP1A1—cardiac atrium—muscle cancer	0.00018	0.00495	CbGeAlD
Erlotinib—Bone pain—Doxorubicin—muscle cancer	0.00018	0.00308	CcSEcCtD
Erlotinib—Inflammation—Doxorubicin—muscle cancer	0.000178	0.00304	CcSEcCtD
Erlotinib—Hepatobiliary disease—Etoposide—muscle cancer	0.000176	0.00301	CcSEcCtD
Erlotinib—Musculoskeletal pain—Doxorubicin—muscle cancer	0.000175	0.00299	CcSEcCtD
Erlotinib—Back pain—Vincristine—muscle cancer	0.000174	0.00297	CcSEcCtD
Erlotinib—Sepsis—Methotrexate—muscle cancer	0.000173	0.00296	CcSEcCtD
Erlotinib—Hepatocellular injury—Doxorubicin—muscle cancer	0.000173	0.00295	CcSEcCtD
Erlotinib—Myalgia—Dactinomycin—muscle cancer	0.000171	0.00292	CcSEcCtD
Erlotinib—Melaena—Doxorubicin—muscle cancer	0.000169	0.00288	CcSEcCtD
Erlotinib—Colitis—Doxorubicin—muscle cancer	0.000166	0.00283	CcSEcCtD
Erlotinib—Urinary tract disorder—Etoposide—muscle cancer	0.000165	0.00282	CcSEcCtD
Erlotinib—Skin exfoliation—Doxorubicin—muscle cancer	0.000165	0.00282	CcSEcCtD
Erlotinib—Oedema—Dactinomycin—muscle cancer	0.000164	0.0028	CcSEcCtD
Erlotinib—Urethral disorder—Etoposide—muscle cancer	0.000164	0.0028	CcSEcCtD
Erlotinib—Infection—Dactinomycin—muscle cancer	0.000163	0.00279	CcSEcCtD
Erlotinib—Neuropathy—Doxorubicin—muscle cancer	0.000162	0.00277	CcSEcCtD
Erlotinib—Hepatic failure—Methotrexate—muscle cancer	0.000161	0.00275	CcSEcCtD
Erlotinib—Thrombocytopenia—Dactinomycin—muscle cancer	0.000161	0.00275	CcSEcCtD
Erlotinib—ABCG2—bone marrow—muscle cancer	0.00016	0.0044	CbGeAlD
Erlotinib—Dry eye—Doxorubicin—muscle cancer	0.000159	0.00272	CcSEcCtD
Erlotinib—Erythema multiforme—Etoposide—muscle cancer	0.000158	0.0027	CcSEcCtD
Erlotinib—CYP2C8—vagina—muscle cancer	0.000158	0.00434	CbGeAlD
Erlotinib—Renal failure acute—Methotrexate—muscle cancer	0.000157	0.00268	CcSEcCtD
Erlotinib—Anorexia—Dactinomycin—muscle cancer	0.000156	0.00267	CcSEcCtD
Erlotinib—Eye disorder—Etoposide—muscle cancer	0.000156	0.00267	CcSEcCtD
Erlotinib—ABCG2—vagina—muscle cancer	0.000154	0.00422	CbGeAlD
Erlotinib—Myalgia—Vincristine—muscle cancer	0.000153	0.00261	CcSEcCtD
Erlotinib—Mediastinal disorder—Etoposide—muscle cancer	0.000151	0.00257	CcSEcCtD
Erlotinib—Chills—Etoposide—muscle cancer	0.00015	0.00256	CcSEcCtD
Erlotinib—Sepsis—Doxorubicin—muscle cancer	0.00015	0.00256	CcSEcCtD
Erlotinib—Musculoskeletal discomfort—Dactinomycin—muscle cancer	0.000149	0.00255	CcSEcCtD
Erlotinib—CYP3A4—renal system—muscle cancer	0.000148	0.00406	CbGeAlD
Erlotinib—Alopecia—Etoposide—muscle cancer	0.000148	0.00252	CcSEcCtD
Erlotinib—Cerebrovascular accident—Methotrexate—muscle cancer	0.000148	0.00252	CcSEcCtD
Erlotinib—Oedema—Vincristine—muscle cancer	0.000147	0.00251	CcSEcCtD
Erlotinib—CYP1A1—vagina—muscle cancer	0.000146	0.00401	CbGeAlD
Erlotinib—Infection—Vincristine—muscle cancer	0.000146	0.00249	CcSEcCtD
Erlotinib—CYP2D6—renal system—muscle cancer	0.000145	0.00399	CbGeAlD
Erlotinib—Nervous system disorder—Vincristine—muscle cancer	0.000144	0.00246	CcSEcCtD
Erlotinib—Thrombocytopenia—Vincristine—muscle cancer	0.000144	0.00245	CcSEcCtD
Erlotinib—CYP3A5—vagina—muscle cancer	0.000143	0.00392	CbGeAlD
Erlotinib—Decreased appetite—Dactinomycin—muscle cancer	0.000143	0.00244	CcSEcCtD
Erlotinib—Fatigue—Dactinomycin—muscle cancer	0.000141	0.00242	CcSEcCtD
Erlotinib—CYP2C8—testis—muscle cancer	0.000141	0.00387	CbGeAlD
Erlotinib—Back pain—Etoposide—muscle cancer	0.000141	0.00241	CcSEcCtD
Erlotinib—Pain—Dactinomycin—muscle cancer	0.00014	0.0024	CcSEcCtD
Erlotinib—Anorexia—Vincristine—muscle cancer	0.00014	0.00239	CcSEcCtD
Erlotinib—Hepatic failure—Doxorubicin—muscle cancer	0.000139	0.00238	CcSEcCtD
Erlotinib—ABCB1—embryo—muscle cancer	0.000138	0.00379	CbGeAlD
Erlotinib—ABCG2—testis—muscle cancer	0.000137	0.00376	CbGeAlD
Erlotinib—Renal failure acute—Doxorubicin—muscle cancer	0.000136	0.00232	CcSEcCtD
Erlotinib—CYP1A1—head—muscle cancer	0.000135	0.0037	CbGeAlD
Erlotinib—Gastrointestinal pain—Dactinomycin—muscle cancer	0.000134	0.00229	CcSEcCtD
Erlotinib—Musculoskeletal discomfort—Vincristine—muscle cancer	0.000134	0.00228	CcSEcCtD
Erlotinib—Insomnia—Vincristine—muscle cancer	0.000133	0.00227	CcSEcCtD
Erlotinib—Renal impairment—Doxorubicin—muscle cancer	0.000132	0.00225	CcSEcCtD
Erlotinib—Dermatitis bullous—Doxorubicin—muscle cancer	0.000131	0.00224	CcSEcCtD
Erlotinib—Toxic epidermal necrolysis—Methotrexate—muscle cancer	0.00013	0.00223	CcSEcCtD
Erlotinib—Abdominal pain—Dactinomycin—muscle cancer	0.00013	0.00222	CcSEcCtD
Erlotinib—Body temperature increased—Dactinomycin—muscle cancer	0.00013	0.00222	CcSEcCtD
Erlotinib—Loss of consciousness—Etoposide—muscle cancer	0.000128	0.00219	CcSEcCtD
Erlotinib—Cerebrovascular accident—Doxorubicin—muscle cancer	0.000128	0.00219	CcSEcCtD
Erlotinib—Decreased appetite—Vincristine—muscle cancer	0.000127	0.00218	CcSEcCtD
Erlotinib—Cough—Etoposide—muscle cancer	0.000127	0.00217	CcSEcCtD
Erlotinib—Gastrointestinal disorder—Vincristine—muscle cancer	0.000127	0.00216	CcSEcCtD
Erlotinib—Fatigue—Vincristine—muscle cancer	0.000126	0.00216	CcSEcCtD
Erlotinib—Constipation—Vincristine—muscle cancer	0.000125	0.00214	CcSEcCtD
Erlotinib—Pain—Vincristine—muscle cancer	0.000125	0.00214	CcSEcCtD
Erlotinib—Gastrointestinal haemorrhage—Doxorubicin—muscle cancer	0.000125	0.00214	CcSEcCtD
Erlotinib—Chest pain—Etoposide—muscle cancer	0.000124	0.00212	CcSEcCtD
Erlotinib—Unspecified disorder of skin and subcutaneous tissue—Etoposide—muscle cancer	0.000123	0.0021	CcSEcCtD
Erlotinib—Pancreatitis—Methotrexate—muscle cancer	0.000123	0.0021	CcSEcCtD
Erlotinib—Gastrointestinal pain—Vincristine—muscle cancer	0.00012	0.00205	CcSEcCtD
Erlotinib—Infection—Etoposide—muscle cancer	0.000118	0.00202	CcSEcCtD
Erlotinib—Asthenia—Dactinomycin—muscle cancer	0.000118	0.00201	CcSEcCtD
Erlotinib—Neutropenia—Methotrexate—muscle cancer	0.000117	0.002	CcSEcCtD
Erlotinib—Dehydration—Doxorubicin—muscle cancer	0.000117	0.00199	CcSEcCtD
Erlotinib—Thrombocytopenia—Etoposide—muscle cancer	0.000116	0.00199	CcSEcCtD
Erlotinib—Abdominal pain—Vincristine—muscle cancer	0.000116	0.00198	CcSEcCtD
Erlotinib—Body temperature increased—Vincristine—muscle cancer	0.000116	0.00198	CcSEcCtD
Erlotinib—Skin disorder—Etoposide—muscle cancer	0.000115	0.00197	CcSEcCtD
Erlotinib—Dry skin—Doxorubicin—muscle cancer	0.000115	0.00196	CcSEcCtD
Erlotinib—Hypokalaemia—Doxorubicin—muscle cancer	0.000114	0.00195	CcSEcCtD
Erlotinib—Anorexia—Etoposide—muscle cancer	0.000113	0.00193	CcSEcCtD
Erlotinib—Toxic epidermal necrolysis—Doxorubicin—muscle cancer	0.000113	0.00193	CcSEcCtD
Erlotinib—Diarrhoea—Dactinomycin—muscle cancer	0.000112	0.00192	CcSEcCtD
Erlotinib—Pneumonia—Methotrexate—muscle cancer	0.000112	0.00192	CcSEcCtD
Erlotinib—Infestation—Methotrexate—muscle cancer	0.000112	0.00191	CcSEcCtD
Erlotinib—Infestation NOS—Methotrexate—muscle cancer	0.000112	0.00191	CcSEcCtD
Erlotinib—Depression—Methotrexate—muscle cancer	0.000111	0.0019	CcSEcCtD
Erlotinib—Gastritis—Doxorubicin—muscle cancer	0.000111	0.0019	CcSEcCtD
Erlotinib—Stevens-Johnson syndrome—Methotrexate—muscle cancer	0.000111	0.00189	CcSEcCtD
Erlotinib—Alanine aminotransferase increased—Doxorubicin—muscle cancer	0.000111	0.00189	CcSEcCtD
Erlotinib—Renal failure—Methotrexate—muscle cancer	0.00011	0.00187	CcSEcCtD
Erlotinib—Stomatitis—Methotrexate—muscle cancer	0.000109	0.00186	CcSEcCtD
Erlotinib—Conjunctivitis—Methotrexate—muscle cancer	0.000108	0.00185	CcSEcCtD
Erlotinib—Dysphagia—Doxorubicin—muscle cancer	0.000108	0.00185	CcSEcCtD
Erlotinib—Pancreatitis—Doxorubicin—muscle cancer	0.000106	0.00181	CcSEcCtD
Erlotinib—Dyspnoea—Etoposide—muscle cancer	0.000106	0.00181	CcSEcCtD
Erlotinib—Hepatobiliary disease—Methotrexate—muscle cancer	0.000105	0.0018	CcSEcCtD
Erlotinib—Epistaxis—Methotrexate—muscle cancer	0.000105	0.0018	CcSEcCtD
Erlotinib—Asthenia—Vincristine—muscle cancer	0.000105	0.0018	CcSEcCtD
Erlotinib—ABCB1—renal system—muscle cancer	0.000105	0.00287	CbGeAlD
Erlotinib—Vomiting—Dactinomycin—muscle cancer	0.000104	0.00178	CcSEcCtD
Erlotinib—Rash—Dactinomycin—muscle cancer	0.000103	0.00177	CcSEcCtD
Erlotinib—Decreased appetite—Etoposide—muscle cancer	0.000103	0.00176	CcSEcCtD
Erlotinib—Gastrointestinal disorder—Etoposide—muscle cancer	0.000103	0.00175	CcSEcCtD
Erlotinib—Fatigue—Etoposide—muscle cancer	0.000102	0.00175	CcSEcCtD
Erlotinib—Pain—Etoposide—muscle cancer	0.000102	0.00174	CcSEcCtD
Erlotinib—Constipation—Etoposide—muscle cancer	0.000102	0.00174	CcSEcCtD
Erlotinib—Neutropenia—Doxorubicin—muscle cancer	0.000101	0.00173	CcSEcCtD
Erlotinib—Haemoglobin—Methotrexate—muscle cancer	0.000101	0.00172	CcSEcCtD
Erlotinib—Diarrhoea—Vincristine—muscle cancer	0.0001	0.00171	CcSEcCtD
Erlotinib—Haemorrhage—Methotrexate—muscle cancer	0.0001	0.00171	CcSEcCtD
Erlotinib—Hepatitis—Methotrexate—muscle cancer	0.0001	0.00171	CcSEcCtD
Erlotinib—Urinary tract disorder—Methotrexate—muscle cancer	9.89e-05	0.00169	CcSEcCtD
Erlotinib—Urethral disorder—Methotrexate—muscle cancer	9.81e-05	0.00168	CcSEcCtD
Erlotinib—Weight decreased—Doxorubicin—muscle cancer	9.8e-05	0.00167	CcSEcCtD
Erlotinib—Nausea—Dactinomycin—muscle cancer	9.74e-05	0.00167	CcSEcCtD
Erlotinib—CYP2D6—head—muscle cancer	9.73e-05	0.00267	CbGeAlD
Erlotinib—Pneumonia—Doxorubicin—muscle cancer	9.71e-05	0.00166	CcSEcCtD
Erlotinib—Gastrointestinal pain—Etoposide—muscle cancer	9.71e-05	0.00166	CcSEcCtD
Erlotinib—Dizziness—Vincristine—muscle cancer	9.69e-05	0.00166	CcSEcCtD
Erlotinib—Infestation—Doxorubicin—muscle cancer	9.66e-05	0.00165	CcSEcCtD
Erlotinib—Infestation NOS—Doxorubicin—muscle cancer	9.66e-05	0.00165	CcSEcCtD
Erlotinib—Stevens-Johnson syndrome—Doxorubicin—muscle cancer	9.57e-05	0.00164	CcSEcCtD
Erlotinib—Renal failure—Doxorubicin—muscle cancer	9.49e-05	0.00162	CcSEcCtD
Erlotinib—Erythema multiforme—Methotrexate—muscle cancer	9.47e-05	0.00162	CcSEcCtD
Erlotinib—Neuropathy peripheral—Doxorubicin—muscle cancer	9.47e-05	0.00162	CcSEcCtD
Erlotinib—Stomatitis—Doxorubicin—muscle cancer	9.41e-05	0.00161	CcSEcCtD
Erlotinib—CYP2D6—testis—muscle cancer	9.4e-05	0.00258	CbGeAlD
Erlotinib—Body temperature increased—Etoposide—muscle cancer	9.39e-05	0.0016	CcSEcCtD
Erlotinib—Abdominal pain—Etoposide—muscle cancer	9.39e-05	0.0016	CcSEcCtD
Erlotinib—Conjunctivitis—Doxorubicin—muscle cancer	9.39e-05	0.0016	CcSEcCtD
Erlotinib—Eye disorder—Methotrexate—muscle cancer	9.36e-05	0.0016	CcSEcCtD
Erlotinib—Vomiting—Vincristine—muscle cancer	9.32e-05	0.00159	CcSEcCtD
Erlotinib—Rash—Vincristine—muscle cancer	9.24e-05	0.00158	CcSEcCtD
Erlotinib—Dermatitis—Vincristine—muscle cancer	9.23e-05	0.00158	CcSEcCtD
Erlotinib—Headache—Vincristine—muscle cancer	9.18e-05	0.00157	CcSEcCtD
Erlotinib—Hepatobiliary disease—Doxorubicin—muscle cancer	9.13e-05	0.00156	CcSEcCtD
Erlotinib—Epistaxis—Doxorubicin—muscle cancer	9.11e-05	0.00156	CcSEcCtD
Erlotinib—Mediastinal disorder—Methotrexate—muscle cancer	9.02e-05	0.00154	CcSEcCtD
Erlotinib—Chills—Methotrexate—muscle cancer	8.98e-05	0.00154	CcSEcCtD
Erlotinib—Alopecia—Methotrexate—muscle cancer	8.85e-05	0.00151	CcSEcCtD
Erlotinib—Mental disorder—Methotrexate—muscle cancer	8.77e-05	0.0015	CcSEcCtD
Erlotinib—Malnutrition—Methotrexate—muscle cancer	8.71e-05	0.00149	CcSEcCtD
Erlotinib—Erythema—Methotrexate—muscle cancer	8.71e-05	0.00149	CcSEcCtD
Erlotinib—Haemoglobin—Doxorubicin—muscle cancer	8.71e-05	0.00149	CcSEcCtD
Erlotinib—Nausea—Vincristine—muscle cancer	8.71e-05	0.00149	CcSEcCtD
Erlotinib—Haemorrhage—Doxorubicin—muscle cancer	8.67e-05	0.00148	CcSEcCtD
Erlotinib—Hepatitis—Doxorubicin—muscle cancer	8.67e-05	0.00148	CcSEcCtD
Erlotinib—Urinary tract disorder—Doxorubicin—muscle cancer	8.56e-05	0.00146	CcSEcCtD
Erlotinib—Asthenia—Etoposide—muscle cancer	8.52e-05	0.00146	CcSEcCtD
Erlotinib—Connective tissue disorder—Doxorubicin—muscle cancer	8.52e-05	0.00146	CcSEcCtD
Erlotinib—Urethral disorder—Doxorubicin—muscle cancer	8.5e-05	0.00145	CcSEcCtD
Erlotinib—Back pain—Methotrexate—muscle cancer	8.43e-05	0.00144	CcSEcCtD
Erlotinib—Pruritus—Etoposide—muscle cancer	8.4e-05	0.00144	CcSEcCtD
Erlotinib—Erythema multiforme—Doxorubicin—muscle cancer	8.2e-05	0.0014	CcSEcCtD
Erlotinib—Diarrhoea—Etoposide—muscle cancer	8.12e-05	0.00139	CcSEcCtD
Erlotinib—Eye disorder—Doxorubicin—muscle cancer	8.1e-05	0.00138	CcSEcCtD
Erlotinib—ABCB1—bone marrow—muscle cancer	7.91e-05	0.00217	CbGeAlD
Erlotinib—Dizziness—Etoposide—muscle cancer	7.85e-05	0.00134	CcSEcCtD
Erlotinib—Mediastinal disorder—Doxorubicin—muscle cancer	7.81e-05	0.00134	CcSEcCtD
Erlotinib—Chills—Doxorubicin—muscle cancer	7.78e-05	0.00133	CcSEcCtD
Erlotinib—Arrhythmia—Doxorubicin—muscle cancer	7.74e-05	0.00132	CcSEcCtD
Erlotinib—Alopecia—Doxorubicin—muscle cancer	7.66e-05	0.00131	CcSEcCtD
Erlotinib—Cough—Methotrexate—muscle cancer	7.6e-05	0.0013	CcSEcCtD
Erlotinib—Mental disorder—Doxorubicin—muscle cancer	7.59e-05	0.0013	CcSEcCtD
Erlotinib—ABCB1—vagina—muscle cancer	7.58e-05	0.00208	CbGeAlD
Erlotinib—Vomiting—Etoposide—muscle cancer	7.55e-05	0.00129	CcSEcCtD
Erlotinib—Erythema—Doxorubicin—muscle cancer	7.55e-05	0.00129	CcSEcCtD
Erlotinib—Malnutrition—Doxorubicin—muscle cancer	7.55e-05	0.00129	CcSEcCtD
Erlotinib—Rash—Etoposide—muscle cancer	7.49e-05	0.00128	CcSEcCtD
Erlotinib—Dermatitis—Etoposide—muscle cancer	7.48e-05	0.00128	CcSEcCtD
Erlotinib—Headache—Etoposide—muscle cancer	7.44e-05	0.00127	CcSEcCtD
Erlotinib—Flatulence—Doxorubicin—muscle cancer	7.44e-05	0.00127	CcSEcCtD
Erlotinib—Arthralgia—Methotrexate—muscle cancer	7.42e-05	0.00127	CcSEcCtD
Erlotinib—Myalgia—Methotrexate—muscle cancer	7.42e-05	0.00127	CcSEcCtD
Erlotinib—Chest pain—Methotrexate—muscle cancer	7.42e-05	0.00127	CcSEcCtD
Erlotinib—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—muscle cancer	7.37e-05	0.00126	CcSEcCtD
Erlotinib—Back pain—Doxorubicin—muscle cancer	7.3e-05	0.00125	CcSEcCtD
Erlotinib—Infection—Methotrexate—muscle cancer	7.07e-05	0.00121	CcSEcCtD
Erlotinib—Nausea—Etoposide—muscle cancer	7.05e-05	0.00121	CcSEcCtD
Erlotinib—ABCB1—head—muscle cancer	7e-05	0.00192	CbGeAlD
Erlotinib—Nervous system disorder—Methotrexate—muscle cancer	6.97e-05	0.00119	CcSEcCtD
Erlotinib—Thrombocytopenia—Methotrexate—muscle cancer	6.96e-05	0.00119	CcSEcCtD
Erlotinib—Skin disorder—Methotrexate—muscle cancer	6.91e-05	0.00118	CcSEcCtD
Erlotinib—Anorexia—Methotrexate—muscle cancer	6.78e-05	0.00116	CcSEcCtD
Erlotinib—Syncope—Doxorubicin—muscle cancer	6.77e-05	0.00116	CcSEcCtD
Erlotinib—ABCB1—testis—muscle cancer	6.76e-05	0.00186	CbGeAlD
Erlotinib—Loss of consciousness—Doxorubicin—muscle cancer	6.63e-05	0.00113	CcSEcCtD
Erlotinib—Cough—Doxorubicin—muscle cancer	6.58e-05	0.00113	CcSEcCtD
Erlotinib—Musculoskeletal discomfort—Methotrexate—muscle cancer	6.48e-05	0.00111	CcSEcCtD
Erlotinib—Insomnia—Methotrexate—muscle cancer	6.43e-05	0.0011	CcSEcCtD
Erlotinib—Myalgia—Doxorubicin—muscle cancer	6.42e-05	0.0011	CcSEcCtD
Erlotinib—Arthralgia—Doxorubicin—muscle cancer	6.42e-05	0.0011	CcSEcCtD
Erlotinib—Chest pain—Doxorubicin—muscle cancer	6.42e-05	0.0011	CcSEcCtD
Erlotinib—Anxiety—Doxorubicin—muscle cancer	6.4e-05	0.00109	CcSEcCtD
Erlotinib—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—muscle cancer	6.38e-05	0.00109	CcSEcCtD
Erlotinib—Dyspnoea—Methotrexate—muscle cancer	6.34e-05	0.00108	CcSEcCtD
Erlotinib—Dyspepsia—Methotrexate—muscle cancer	6.26e-05	0.00107	CcSEcCtD
Erlotinib—Decreased appetite—Methotrexate—muscle cancer	6.18e-05	0.00106	CcSEcCtD
Erlotinib—Oedema—Doxorubicin—muscle cancer	6.16e-05	0.00105	CcSEcCtD
Erlotinib—Gastrointestinal disorder—Methotrexate—muscle cancer	6.14e-05	0.00105	CcSEcCtD
Erlotinib—Fatigue—Methotrexate—muscle cancer	6.13e-05	0.00105	CcSEcCtD
Erlotinib—Infection—Doxorubicin—muscle cancer	6.12e-05	0.00105	CcSEcCtD
Erlotinib—Pain—Methotrexate—muscle cancer	6.08e-05	0.00104	CcSEcCtD
Erlotinib—Shock—Doxorubicin—muscle cancer	6.06e-05	0.00104	CcSEcCtD
Erlotinib—Nervous system disorder—Doxorubicin—muscle cancer	6.04e-05	0.00103	CcSEcCtD
Erlotinib—Thrombocytopenia—Doxorubicin—muscle cancer	6.03e-05	0.00103	CcSEcCtD
Erlotinib—Skin disorder—Doxorubicin—muscle cancer	5.98e-05	0.00102	CcSEcCtD
Erlotinib—Anorexia—Doxorubicin—muscle cancer	5.87e-05	0.001	CcSEcCtD
Erlotinib—Gastrointestinal pain—Methotrexate—muscle cancer	5.82e-05	0.000994	CcSEcCtD
Erlotinib—Body temperature increased—Methotrexate—muscle cancer	5.62e-05	0.000961	CcSEcCtD
Erlotinib—Abdominal pain—Methotrexate—muscle cancer	5.62e-05	0.000961	CcSEcCtD
Erlotinib—Musculoskeletal discomfort—Doxorubicin—muscle cancer	5.61e-05	0.000959	CcSEcCtD
Erlotinib—Insomnia—Doxorubicin—muscle cancer	5.57e-05	0.000952	CcSEcCtD
Erlotinib—Dyspnoea—Doxorubicin—muscle cancer	5.49e-05	0.000938	CcSEcCtD
Erlotinib—Dyspepsia—Doxorubicin—muscle cancer	5.42e-05	0.000926	CcSEcCtD
Erlotinib—Decreased appetite—Doxorubicin—muscle cancer	5.35e-05	0.000915	CcSEcCtD
Erlotinib—Gastrointestinal disorder—Doxorubicin—muscle cancer	5.32e-05	0.000909	CcSEcCtD
Erlotinib—Fatigue—Doxorubicin—muscle cancer	5.31e-05	0.000907	CcSEcCtD
Erlotinib—Constipation—Doxorubicin—muscle cancer	5.27e-05	0.0009	CcSEcCtD
Erlotinib—Pain—Doxorubicin—muscle cancer	5.27e-05	0.0009	CcSEcCtD
Erlotinib—Asthenia—Methotrexate—muscle cancer	5.1e-05	0.000872	CcSEcCtD
Erlotinib—Gastrointestinal pain—Doxorubicin—muscle cancer	5.04e-05	0.000861	CcSEcCtD
Erlotinib—Pruritus—Methotrexate—muscle cancer	5.03e-05	0.00086	CcSEcCtD
Erlotinib—Abdominal pain—Doxorubicin—muscle cancer	4.87e-05	0.000832	CcSEcCtD
Erlotinib—Body temperature increased—Doxorubicin—muscle cancer	4.87e-05	0.000832	CcSEcCtD
Erlotinib—Diarrhoea—Methotrexate—muscle cancer	4.87e-05	0.000832	CcSEcCtD
Erlotinib—Dizziness—Methotrexate—muscle cancer	4.7e-05	0.000804	CcSEcCtD
Erlotinib—Vomiting—Methotrexate—muscle cancer	4.52e-05	0.000773	CcSEcCtD
Erlotinib—Rash—Methotrexate—muscle cancer	4.48e-05	0.000766	CcSEcCtD
Erlotinib—Dermatitis—Methotrexate—muscle cancer	4.48e-05	0.000766	CcSEcCtD
Erlotinib—Headache—Methotrexate—muscle cancer	4.46e-05	0.000761	CcSEcCtD
Erlotinib—Asthenia—Doxorubicin—muscle cancer	4.42e-05	0.000755	CcSEcCtD
Erlotinib—Pruritus—Doxorubicin—muscle cancer	4.36e-05	0.000745	CcSEcCtD
Erlotinib—EGFR—GAB1 signalosome—MDM2—muscle cancer	4.35e-05	0.00129	CbGpPWpGaD
Erlotinib—ABL2—Axon guidance—VEGFA—muscle cancer	4.34e-05	0.00129	CbGpPWpGaD
Erlotinib—EGFR—B Cell Activation—FOXO1—muscle cancer	4.32e-05	0.00128	CbGpPWpGaD
Erlotinib—EGFR—Signaling by NGF—FOXO4—muscle cancer	4.3e-05	0.00128	CbGpPWpGaD
Erlotinib—CYP2C8—Arachidonic acid metabolism—PTGS2—muscle cancer	4.3e-05	0.00128	CbGpPWpGaD
Erlotinib—EGFR—Signaling by SCF-KIT—KIT—muscle cancer	4.26e-05	0.00127	CbGpPWpGaD
Erlotinib—EGFR—Role of LAT2/NTAL/LAB on calcium mobilization—MDM2—muscle cancer	4.25e-05	0.00126	CbGpPWpGaD
Erlotinib—Nausea—Methotrexate—muscle cancer	4.22e-05	0.000722	CcSEcCtD
Erlotinib—Diarrhoea—Doxorubicin—muscle cancer	4.21e-05	0.00072	CcSEcCtD
Erlotinib—JAK3—Signaling by GPCR—PTCH1—muscle cancer	4.16e-05	0.00124	CbGpPWpGaD
Erlotinib—EGFR—ErbB Signaling Pathway—TP53—muscle cancer	4.15e-05	0.00123	CbGpPWpGaD
Erlotinib—EGFR—NGF signalling via TRKA from the plasma membrane—FOXO1—muscle cancer	4.13e-05	0.00123	CbGpPWpGaD
Erlotinib—ABCB1—Integrated Pancreatic Cancer Pathway—WT1—muscle cancer	4.1e-05	0.00122	CbGpPWpGaD
Erlotinib—EGFR—Developmental Biology—MYOD1—muscle cancer	4.09e-05	0.00121	CbGpPWpGaD
Erlotinib—EGFR—Downstream signaling of activated FGFR—KIT—muscle cancer	4.08e-05	0.00121	CbGpPWpGaD
Erlotinib—Dizziness—Doxorubicin—muscle cancer	4.07e-05	0.000696	CcSEcCtD
Erlotinib—JAK3—Platelet activation, signaling and aggregation—VEGFA—muscle cancer	4.07e-05	0.00121	CbGpPWpGaD
Erlotinib—ABL1—DNA Damage Response—TP53—muscle cancer	4.04e-05	0.0012	CbGpPWpGaD
Erlotinib—EGFR—Signaling by ERBB4—KIT—muscle cancer	4.02e-05	0.00119	CbGpPWpGaD
Erlotinib—MKNK1—Disease—FOXO4—muscle cancer	4e-05	0.00119	CbGpPWpGaD
Erlotinib—CYP1A1—Aryl Hydrocarbon Receptor—VEGFA—muscle cancer	3.95e-05	0.00117	CbGpPWpGaD
Erlotinib—Vomiting—Doxorubicin—muscle cancer	3.92e-05	0.000669	CcSEcCtD
Erlotinib—ABL1—miRNA Regulation of DNA Damage Response—TP53—muscle cancer	3.9e-05	0.00116	CbGpPWpGaD
Erlotinib—Rash—Doxorubicin—muscle cancer	3.88e-05	0.000664	CcSEcCtD
Erlotinib—Dermatitis—Doxorubicin—muscle cancer	3.88e-05	0.000663	CcSEcCtD
Erlotinib—JAK3—GPCR downstream signaling—CNR1—muscle cancer	3.87e-05	0.00115	CbGpPWpGaD
Erlotinib—Headache—Doxorubicin—muscle cancer	3.86e-05	0.000659	CcSEcCtD
Erlotinib—EGFR—Downstream signal transduction—KIT—muscle cancer	3.83e-05	0.00114	CbGpPWpGaD
Erlotinib—EGFR—Signaling by FGFR—KIT—muscle cancer	3.82e-05	0.00113	CbGpPWpGaD
Erlotinib—EGFR—Signaling by ERBB2—KIT—muscle cancer	3.8e-05	0.00113	CbGpPWpGaD
Erlotinib—EGFR—DAP12 signaling—KIT—muscle cancer	3.78e-05	0.00112	CbGpPWpGaD
Erlotinib—MAP2K5—Focal Adhesion—VEGFA—muscle cancer	3.74e-05	0.00111	CbGpPWpGaD
Erlotinib—EGFR—Developmental Biology—MED12—muscle cancer	3.74e-05	0.00111	CbGpPWpGaD
Erlotinib—EGFR—Spinal Cord Injury—PTGS2—muscle cancer	3.73e-05	0.00111	CbGpPWpGaD
Erlotinib—EGFR—Downstream signaling events of B Cell Receptor (BCR)—KIT—muscle cancer	3.72e-05	0.00111	CbGpPWpGaD
Erlotinib—ABL1—Integrated Breast Cancer Pathway—MDM2—muscle cancer	3.72e-05	0.0011	CbGpPWpGaD
Erlotinib—EPHA6—Axon guidance—VEGFA—muscle cancer	3.66e-05	0.00109	CbGpPWpGaD
Erlotinib—Nausea—Doxorubicin—muscle cancer	3.66e-05	0.000625	CcSEcCtD
Erlotinib—EGFR—Signaling by FGFR in disease—KIT—muscle cancer	3.55e-05	0.00106	CbGpPWpGaD
Erlotinib—EGFR—Fc epsilon receptor (FCERI) signaling—KIT—muscle cancer	3.55e-05	0.00106	CbGpPWpGaD
Erlotinib—EGFR—DAP12 interactions—KIT—muscle cancer	3.55e-05	0.00106	CbGpPWpGaD
Erlotinib—MAP2K5—Signaling by NGF—MDM2—muscle cancer	3.55e-05	0.00106	CbGpPWpGaD
Erlotinib—EGFR—Signaling by EGFR—KIT—muscle cancer	3.52e-05	0.00105	CbGpPWpGaD
Erlotinib—JAK3—Signaling by GPCR—CNR1—muscle cancer	3.51e-05	0.00104	CbGpPWpGaD
Erlotinib—EGFR—Rac1/Pak1/p38/MMP-2 pathway—TP53—muscle cancer	3.49e-05	0.00104	CbGpPWpGaD
Erlotinib—EGFR—Signaling by EGFR in Cancer—KIT—muscle cancer	3.49e-05	0.00104	CbGpPWpGaD
Erlotinib—EGFR—Signaling by PDGF—KIT—muscle cancer	3.48e-05	0.00103	CbGpPWpGaD
Erlotinib—EGFR—Adaptive Immune System—CD34—muscle cancer	3.47e-05	0.00103	CbGpPWpGaD
Erlotinib—CYP1B1—Metabolism of lipids and lipoproteins—MED12—muscle cancer	3.43e-05	0.00102	CbGpPWpGaD
Erlotinib—EGFR—Direct p53 effectors—MDM2—muscle cancer	3.38e-05	0.001	CbGpPWpGaD
Erlotinib—EGFR—Signaling by SCF-KIT—MDM2—muscle cancer	3.36e-05	0.000997	CbGpPWpGaD
Erlotinib—ABL1—Retinoblastoma (RB) in Cancer—TP53—muscle cancer	3.32e-05	0.000985	CbGpPWpGaD
Erlotinib—CYP1A2—Tryptophan metabolism—MDM2—muscle cancer	3.32e-05	0.000984	CbGpPWpGaD
Erlotinib—EGFR—B Cell Activation—KIT—muscle cancer	3.29e-05	0.000977	CbGpPWpGaD
Erlotinib—JAK3—Immune System—FOXO4—muscle cancer	3.27e-05	0.00097	CbGpPWpGaD
Erlotinib—MKNK1—Signaling Pathways—PTCH1—muscle cancer	3.26e-05	0.000967	CbGpPWpGaD
Erlotinib—EGFR—Downstream signaling of activated FGFR—MDM2—muscle cancer	3.21e-05	0.000954	CbGpPWpGaD
Erlotinib—CYP1A2—Aryl Hydrocarbon Receptor—PTGS2—muscle cancer	3.2e-05	0.000949	CbGpPWpGaD
Erlotinib—EGFR—Integrated Breast Cancer Pathway—MDM2—muscle cancer	3.18e-05	0.000944	CbGpPWpGaD
Erlotinib—EGFR—Signaling by NGF—FOXO1—muscle cancer	3.18e-05	0.000944	CbGpPWpGaD
Erlotinib—EGFR—Signaling by ERBB4—MDM2—muscle cancer	3.16e-05	0.000939	CbGpPWpGaD
Erlotinib—EGFR—NGF signalling via TRKA from the plasma membrane—KIT—muscle cancer	3.15e-05	0.000935	CbGpPWpGaD
Erlotinib—MAP2K5—MAPK Signaling Pathway—TP53—muscle cancer	3.12e-05	0.000927	CbGpPWpGaD
Erlotinib—ABL2—Developmental Biology—VEGFA—muscle cancer	3.1e-05	0.00092	CbGpPWpGaD
Erlotinib—ABL1—Integrated Pancreatic Cancer Pathway—MDM2—muscle cancer	3.08e-05	0.000915	CbGpPWpGaD
Erlotinib—EGFR—Downstream signal transduction—MDM2—muscle cancer	3.02e-05	0.000897	CbGpPWpGaD
Erlotinib—EGFR—Signaling by FGFR—MDM2—muscle cancer	3.01e-05	0.000892	CbGpPWpGaD
Erlotinib—ABCB1—Integrated Pancreatic Cancer Pathway—BUB1B—muscle cancer	3e-05	0.000891	CbGpPWpGaD
Erlotinib—EGFR—Signaling by ERBB2—MDM2—muscle cancer	2.99e-05	0.000888	CbGpPWpGaD
Erlotinib—CYP1A2—Arachidonic acid metabolism—PTGS2—muscle cancer	2.99e-05	0.000888	CbGpPWpGaD
Erlotinib—EGFR—DAP12 signaling—MDM2—muscle cancer	2.98e-05	0.000884	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways in Glioblastoma—TP53—muscle cancer	2.97e-05	0.000883	CbGpPWpGaD
Erlotinib—ABL1—Integrated Pancreatic Cancer Pathway—PTGS2—muscle cancer	2.97e-05	0.000882	CbGpPWpGaD
Erlotinib—MKNK1—Disease—FOXO1—muscle cancer	2.95e-05	0.000877	CbGpPWpGaD
Erlotinib—EGFR—Downstream signaling events of B Cell Receptor (BCR)—MDM2—muscle cancer	2.93e-05	0.000871	CbGpPWpGaD
Erlotinib—ABL1—Cell Cycle—TP53—muscle cancer	2.92e-05	0.000868	CbGpPWpGaD
Erlotinib—UGT1A1—Metabolism—FH—muscle cancer	2.9e-05	0.00086	CbGpPWpGaD
Erlotinib—ABL1—Innate Immune System—FOXO4—muscle cancer	2.87e-05	0.000853	CbGpPWpGaD
Erlotinib—ABL1—Integrated Breast Cancer Pathway—VEGFA—muscle cancer	2.83e-05	0.000839	CbGpPWpGaD
Erlotinib—MKNK1—Signaling Pathways—FOXO4—muscle cancer	2.8e-05	0.000832	CbGpPWpGaD
Erlotinib—EGFR—Signaling by FGFR in disease—MDM2—muscle cancer	2.8e-05	0.000831	CbGpPWpGaD
Erlotinib—EGFR—Fc epsilon receptor (FCERI) signaling—MDM2—muscle cancer	2.8e-05	0.000831	CbGpPWpGaD
Erlotinib—EGFR—DAP12 interactions—MDM2—muscle cancer	2.8e-05	0.000831	CbGpPWpGaD
Erlotinib—EGFR—Signaling by EGFR—MDM2—muscle cancer	2.77e-05	0.000824	CbGpPWpGaD
Erlotinib—ABL1—DNA Damage Response (only ATM dependent)—TP53—muscle cancer	2.77e-05	0.000823	CbGpPWpGaD
Erlotinib—MKNK1—Signaling Pathways—CNR1—muscle cancer	2.75e-05	0.000817	CbGpPWpGaD
Erlotinib—EGFR—Signaling by EGFR in Cancer—MDM2—muscle cancer	2.75e-05	0.000817	CbGpPWpGaD
Erlotinib—EGFR—Signaling by PDGF—MDM2—muscle cancer	2.74e-05	0.000813	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—KIDINS220—muscle cancer	2.73e-05	0.000811	CbGpPWpGaD
Erlotinib—ALB—Selenium Micronutrient Network—PTGS2—muscle cancer	2.72e-05	0.000807	CbGpPWpGaD
Erlotinib—CYP1B1—Metabolism—FH—muscle cancer	2.7e-05	0.000802	CbGpPWpGaD
Erlotinib—EGFR—Integrated Pancreatic Cancer Pathway—MDM2—muscle cancer	2.63e-05	0.000782	CbGpPWpGaD
Erlotinib—EPHA6—Developmental Biology—VEGFA—muscle cancer	2.61e-05	0.000776	CbGpPWpGaD
Erlotinib—ALB—Hemostasis—ANGPT2—muscle cancer	2.59e-05	0.00077	CbGpPWpGaD
Erlotinib—EGFR—B Cell Activation—MDM2—muscle cancer	2.59e-05	0.000769	CbGpPWpGaD
Erlotinib—ABL1—Hemostasis—IGF2—muscle cancer	2.56e-05	0.00076	CbGpPWpGaD
Erlotinib—CYP3A4—Tryptophan metabolism—MDM2—muscle cancer	2.56e-05	0.00076	CbGpPWpGaD
Erlotinib—EGFR—Integrated Pancreatic Cancer Pathway—PTGS2—muscle cancer	2.54e-05	0.000754	CbGpPWpGaD
Erlotinib—CYP1A2—Aryl Hydrocarbon Receptor—VEGFA—muscle cancer	2.52e-05	0.000748	CbGpPWpGaD
Erlotinib—EGFR—NGF signalling via TRKA from the plasma membrane—MDM2—muscle cancer	2.48e-05	0.000736	CbGpPWpGaD
Erlotinib—ABL1—Immune System—CD34—muscle cancer	2.46e-05	0.000731	CbGpPWpGaD
Erlotinib—ABCG2—Metabolism—FH—muscle cancer	2.46e-05	0.00073	CbGpPWpGaD
Erlotinib—JAK3—Signaling Pathways—PTCH1—muscle cancer	2.46e-05	0.00073	CbGpPWpGaD
Erlotinib—EGFR—Innate Immune System—FOXO4—muscle cancer	2.45e-05	0.000729	CbGpPWpGaD
Erlotinib—ALB—Platelet activation, signaling and aggregation—IGF2—muscle cancer	2.45e-05	0.000726	CbGpPWpGaD
Erlotinib—EGFR—Signaling by NGF—KIT—muscle cancer	2.42e-05	0.000719	CbGpPWpGaD
Erlotinib—EGFR—Integrated Breast Cancer Pathway—VEGFA—muscle cancer	2.41e-05	0.000717	CbGpPWpGaD
Erlotinib—JAK3—Immune System—FOXO1—muscle cancer	2.41e-05	0.000717	CbGpPWpGaD
Erlotinib—ABL1—Developmental Biology—FOXO1—muscle cancer	2.4e-05	0.000713	CbGpPWpGaD
Erlotinib—ABCB1—HIF-1-alpha transcription factor network—VEGFA—muscle cancer	2.36e-05	0.000701	CbGpPWpGaD
Erlotinib—EGFR—Adaptive Immune System—FOXO4—muscle cancer	2.36e-05	0.0007	CbGpPWpGaD
Erlotinib—ABL1—Integrated Pancreatic Cancer Pathway—VEGFA—muscle cancer	2.34e-05	0.000695	CbGpPWpGaD
Erlotinib—ABL1—Factors involved in megakaryocyte development and platelet production—TP53—muscle cancer	2.32e-05	0.000689	CbGpPWpGaD
Erlotinib—ALB—Platelet degranulation—VEGFA—muscle cancer	2.31e-05	0.000686	CbGpPWpGaD
Erlotinib—MKNK1—Disease—KIT—muscle cancer	2.25e-05	0.000669	CbGpPWpGaD
Erlotinib—MKNK1—Signaling Pathways—IGF2—muscle cancer	2.25e-05	0.000668	CbGpPWpGaD
Erlotinib—EGFR—Spinal Cord Injury—TP53—muscle cancer	2.22e-05	0.00066	CbGpPWpGaD
Erlotinib—ALB—Response to elevated platelet cytosolic Ca2+—VEGFA—muscle cancer	2.2e-05	0.000654	CbGpPWpGaD
Erlotinib—ABL1—Integrated Breast Cancer Pathway—TP53—muscle cancer	2.13e-05	0.000634	CbGpPWpGaD
Erlotinib—ABL1—Innate Immune System—FOXO1—muscle cancer	2.12e-05	0.00063	CbGpPWpGaD
Erlotinib—JAK3—Signaling Pathways—FOXO4—muscle cancer	2.11e-05	0.000627	CbGpPWpGaD
Erlotinib—CYP1A1—Metabolism of lipids and lipoproteins—MED12—muscle cancer	2.11e-05	0.000627	CbGpPWpGaD
Erlotinib—EGFR—Immune System—CD34—muscle cancer	2.1e-05	0.000624	CbGpPWpGaD
Erlotinib—JAK3—Hemostasis—VEGFA—muscle cancer	2.1e-05	0.000623	CbGpPWpGaD
Erlotinib—JAK3—Signaling Pathways—CNR1—muscle cancer	2.07e-05	0.000616	CbGpPWpGaD
Erlotinib—MKNK1—Signaling Pathways—FOXO1—muscle cancer	2.07e-05	0.000614	CbGpPWpGaD
Erlotinib—EGFR—Developmental Biology—FOXO1—muscle cancer	2.05e-05	0.000609	CbGpPWpGaD
Erlotinib—ABCB1—Allograft Rejection—VEGFA—muscle cancer	2.05e-05	0.000608	CbGpPWpGaD
Erlotinib—ALB—Folate Metabolism—TP53—muscle cancer	2.04e-05	0.000605	CbGpPWpGaD
Erlotinib—EGFR—Focal Adhesion—VEGFA—muscle cancer	2.01e-05	0.000596	CbGpPWpGaD
Erlotinib—MAP2K5—Signaling Pathways—PTCH1—muscle cancer	2e-05	0.000595	CbGpPWpGaD
Erlotinib—EGFR—Integrated Pancreatic Cancer Pathway—VEGFA—muscle cancer	2e-05	0.000594	CbGpPWpGaD
Erlotinib—EGFR—Direct p53 effectors—TP53—muscle cancer	1.94e-05	0.000575	CbGpPWpGaD
Erlotinib—CYP2C8—Metabolism of lipids and lipoproteins—MED12—muscle cancer	1.93e-05	0.000575	CbGpPWpGaD
Erlotinib—ALB—Metabolism of lipids and lipoproteins—MED12—muscle cancer	1.92e-05	0.000571	CbGpPWpGaD
Erlotinib—EGFR—Signaling by NGF—MDM2—muscle cancer	1.91e-05	0.000566	CbGpPWpGaD
Erlotinib—JAK3—Immune System—KIT—muscle cancer	1.84e-05	0.000546	CbGpPWpGaD
Erlotinib—EGFR—Integrated Breast Cancer Pathway—TP53—muscle cancer	1.82e-05	0.000542	CbGpPWpGaD
Erlotinib—EGFR—Signaling by GPCR—PTCH1—muscle cancer	1.82e-05	0.00054	CbGpPWpGaD
Erlotinib—EGFR—Innate Immune System—FOXO1—muscle cancer	1.81e-05	0.000538	CbGpPWpGaD
Erlotinib—MKNK1—Disease—MDM2—muscle cancer	1.77e-05	0.000527	CbGpPWpGaD
Erlotinib—ABL1—Integrated Pancreatic Cancer Pathway—TP53—muscle cancer	1.77e-05	0.000525	CbGpPWpGaD
Erlotinib—CYP3A5—Metabolism—FH—muscle cancer	1.76e-05	0.000523	CbGpPWpGaD
Erlotinib—EGFR—Adaptive Immune System—FOXO1—muscle cancer	1.74e-05	0.000517	CbGpPWpGaD
Erlotinib—MAP2K5—Signaling Pathways—FOXO4—muscle cancer	1.72e-05	0.000511	CbGpPWpGaD
Erlotinib—MKNK1—Disease—PTGS2—muscle cancer	1.71e-05	0.000508	CbGpPWpGaD
Erlotinib—JAK3—Signaling Pathways—IGF2—muscle cancer	1.7e-05	0.000503	CbGpPWpGaD
Erlotinib—MAP2K5—Signaling Pathways—CNR1—muscle cancer	1.69e-05	0.000502	CbGpPWpGaD
Erlotinib—EGFR—MAPK Signaling Pathway—TP53—muscle cancer	1.67e-05	0.000497	CbGpPWpGaD
Erlotinib—ABL1—Immune System—FOXO4—muscle cancer	1.67e-05	0.000497	CbGpPWpGaD
Erlotinib—CYP1A1—Metabolism—FH—muscle cancer	1.66e-05	0.000494	CbGpPWpGaD
Erlotinib—UGT1A1—Metabolism—MED12—muscle cancer	1.64e-05	0.000486	CbGpPWpGaD
Erlotinib—EGFR—Disease—ENO2—muscle cancer	1.62e-05	0.000481	CbGpPWpGaD
Erlotinib—ABL1—Innate Immune System—KIT—muscle cancer	1.62e-05	0.00048	CbGpPWpGaD
Erlotinib—JAK3—Hemostasis—TP53—muscle cancer	1.58e-05	0.000471	CbGpPWpGaD
Erlotinib—MKNK1—Signaling Pathways—KIT—muscle cancer	1.58e-05	0.000468	CbGpPWpGaD
Erlotinib—JAK3—Signaling Pathways—FOXO1—muscle cancer	1.56e-05	0.000463	CbGpPWpGaD
Erlotinib—EGFR—Signaling by GPCR—CNR1—muscle cancer	1.54e-05	0.000456	CbGpPWpGaD
Erlotinib—ABL1—Axon guidance—VEGFA—muscle cancer	1.53e-05	0.000455	CbGpPWpGaD
Erlotinib—CYP1B1—Metabolism—MED12—muscle cancer	1.53e-05	0.000453	CbGpPWpGaD
Erlotinib—CYP2C8—Metabolism—FH—muscle cancer	1.52e-05	0.000453	CbGpPWpGaD
Erlotinib—ALB—Metabolism—FH—muscle cancer	1.52e-05	0.00045	CbGpPWpGaD
Erlotinib—EGFR—Integrated Pancreatic Cancer Pathway—TP53—muscle cancer	1.51e-05	0.000449	CbGpPWpGaD
Erlotinib—UGT1A1—Metabolism—ENO2—muscle cancer	1.49e-05	0.000443	CbGpPWpGaD
Erlotinib—EGFR—Disease—HMGA1—muscle cancer	1.47e-05	0.000437	CbGpPWpGaD
Erlotinib—JAK3—Immune System—MDM2—muscle cancer	1.45e-05	0.00043	CbGpPWpGaD
Erlotinib—EGFR—Immune System—FOXO4—muscle cancer	1.43e-05	0.000424	CbGpPWpGaD
Erlotinib—CYP1B1—Metabolism—ENO2—muscle cancer	1.39e-05	0.000413	CbGpPWpGaD
Erlotinib—ABCG2—Metabolism—MED12—muscle cancer	1.39e-05	0.000412	CbGpPWpGaD
Erlotinib—MAP2K5—Signaling Pathways—IGF2—muscle cancer	1.38e-05	0.00041	CbGpPWpGaD
Erlotinib—EGFR—Innate Immune System—KIT—muscle cancer	1.38e-05	0.00041	CbGpPWpGaD
Erlotinib—CYP1A2—Metabolism of lipids and lipoproteins—MED12—muscle cancer	1.35e-05	0.0004	CbGpPWpGaD
Erlotinib—ABCB1—Integrated Pancreatic Cancer Pathway—MDM2—muscle cancer	1.33e-05	0.000395	CbGpPWpGaD
Erlotinib—ABCB1—Metabolism—FH—muscle cancer	1.33e-05	0.000394	CbGpPWpGaD
Erlotinib—EGFR—Adaptive Immune System—KIT—muscle cancer	1.33e-05	0.000394	CbGpPWpGaD
Erlotinib—EGFR—Disease—FOXO4—muscle cancer	1.32e-05	0.000392	CbGpPWpGaD
Erlotinib—EGFR—Axon guidance—VEGFA—muscle cancer	1.31e-05	0.000389	CbGpPWpGaD
Erlotinib—ABCB1—Integrated Pancreatic Cancer Pathway—PTGS2—muscle cancer	1.28e-05	0.000381	CbGpPWpGaD
Erlotinib—ABL1—Innate Immune System—MDM2—muscle cancer	1.27e-05	0.000378	CbGpPWpGaD
Erlotinib—MAP2K5—Signaling Pathways—FOXO1—muscle cancer	1.27e-05	0.000378	CbGpPWpGaD
Erlotinib—ABCG2—Metabolism—ENO2—muscle cancer	1.27e-05	0.000376	CbGpPWpGaD
Erlotinib—ALB—Hemostasis—IGF2—muscle cancer	1.26e-05	0.000374	CbGpPWpGaD
Erlotinib—CYP2D6—Metabolism—FH—muscle cancer	1.25e-05	0.000372	CbGpPWpGaD
Erlotinib—MKNK1—Signaling Pathways—MDM2—muscle cancer	1.24e-05	0.000369	CbGpPWpGaD
Erlotinib—ABL1—Immune System—FOXO1—muscle cancer	1.24e-05	0.000367	CbGpPWpGaD
Erlotinib—JAK3—Signaling Pathways—KIT—muscle cancer	1.19e-05	0.000353	CbGpPWpGaD
Erlotinib—ABL1—Developmental Biology—VEGFA—muscle cancer	1.09e-05	0.000325	CbGpPWpGaD
Erlotinib—CYP1B1—Metabolism of lipids and lipoproteins—PTGS2—muscle cancer	1.09e-05	0.000323	CbGpPWpGaD
Erlotinib—EGFR—Innate Immune System—MDM2—muscle cancer	1.09e-05	0.000323	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—PTCH1—muscle cancer	1.07e-05	0.000319	CbGpPWpGaD
Erlotinib—ABL1—Hemostasis—VEGFA—muscle cancer	1.07e-05	0.000319	CbGpPWpGaD
Erlotinib—CYP1A2—Metabolism—FH—muscle cancer	1.06e-05	0.000315	CbGpPWpGaD
Erlotinib—EGFR—Immune System—FOXO1—muscle cancer	1.06e-05	0.000313	CbGpPWpGaD
Erlotinib—EGFR—Adaptive Immune System—MDM2—muscle cancer	1.04e-05	0.00031	CbGpPWpGaD
Erlotinib—ALB—Platelet activation, signaling and aggregation—VEGFA—muscle cancer	1.03e-05	0.000304	CbGpPWpGaD
Erlotinib—ABCB1—Integrated Pancreatic Cancer Pathway—VEGFA—muscle cancer	1.01e-05	0.0003	CbGpPWpGaD
Erlotinib—CYP3A5—Metabolism—MED12—muscle cancer	9.95e-06	0.000295	CbGpPWpGaD
Erlotinib—EGFR—Disease—FOXO1—muscle cancer	9.75e-06	0.000289	CbGpPWpGaD
Erlotinib—MAP2K5—Signaling Pathways—KIT—muscle cancer	9.69e-06	0.000288	CbGpPWpGaD
Erlotinib—MKNK1—Signaling Pathways—VEGFA—muscle cancer	9.43e-06	0.00028	CbGpPWpGaD
Erlotinib—ABL1—Immune System—KIT—muscle cancer	9.41e-06	0.00028	CbGpPWpGaD
Erlotinib—CYP1A1—Metabolism—MED12—muscle cancer	9.4e-06	0.000279	CbGpPWpGaD
Erlotinib—JAK3—Signaling Pathways—MDM2—muscle cancer	9.36e-06	0.000278	CbGpPWpGaD
Erlotinib—EGFR—Developmental Biology—VEGFA—muscle cancer	9.35e-06	0.000278	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—FOXO4—muscle cancer	9.24e-06	0.000274	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—CNR1—muscle cancer	9.07e-06	0.000269	CbGpPWpGaD
Erlotinib—CYP3A5—Metabolism—ENO2—muscle cancer	9.07e-06	0.000269	CbGpPWpGaD
Erlotinib—CYP2C8—Metabolism—MED12—muscle cancer	8.62e-06	0.000256	CbGpPWpGaD
Erlotinib—CYP1A1—Metabolism—ENO2—muscle cancer	8.57e-06	0.000254	CbGpPWpGaD
Erlotinib—ALB—Metabolism—MED12—muscle cancer	8.57e-06	0.000254	CbGpPWpGaD
Erlotinib—CYP3A4—Metabolism—FH—muscle cancer	8.18e-06	0.000243	CbGpPWpGaD
Erlotinib—ABL1—Hemostasis—TP53—muscle cancer	8.11e-06	0.000241	CbGpPWpGaD
Erlotinib—EGFR—Immune System—KIT—muscle cancer	8.04e-06	0.000239	CbGpPWpGaD
Erlotinib—CYP2C8—Metabolism—ENO2—muscle cancer	7.86e-06	0.000233	CbGpPWpGaD
Erlotinib—ALB—Metabolism—ENO2—muscle cancer	7.81e-06	0.000232	CbGpPWpGaD
Erlotinib—MAP2K5—Signaling Pathways—MDM2—muscle cancer	7.63e-06	0.000227	CbGpPWpGaD
Erlotinib—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—muscle cancer	7.63e-06	0.000227	CbGpPWpGaD
Erlotinib—ABCB1—Metabolism—MED12—muscle cancer	7.51e-06	0.000223	CbGpPWpGaD
Erlotinib—EGFR—Disease—KIT—muscle cancer	7.43e-06	0.000221	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—IGF2—muscle cancer	7.42e-06	0.00022	CbGpPWpGaD
Erlotinib—ABL1—Immune System—MDM2—muscle cancer	7.41e-06	0.00022	CbGpPWpGaD
Erlotinib—MKNK1—Signaling Pathways—TP53—muscle cancer	7.12e-06	0.000212	CbGpPWpGaD
Erlotinib—JAK3—Signaling Pathways—VEGFA—muscle cancer	7.11e-06	0.000211	CbGpPWpGaD
Erlotinib—CYP2D6—Metabolism—MED12—muscle cancer	7.07e-06	0.00021	CbGpPWpGaD
Erlotinib—ABCB1—Metabolism—ENO2—muscle cancer	6.84e-06	0.000203	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—FOXO1—muscle cancer	6.83e-06	0.000203	CbGpPWpGaD
Erlotinib—CYP1A1—Metabolism of lipids and lipoproteins—PTGS2—muscle cancer	6.7e-06	0.000199	CbGpPWpGaD
Erlotinib—CYP2D6—Metabolism—ENO2—muscle cancer	6.45e-06	0.000191	CbGpPWpGaD
Erlotinib—EGFR—Immune System—MDM2—muscle cancer	6.34e-06	0.000188	CbGpPWpGaD
Erlotinib—CYP2C8—Metabolism of lipids and lipoproteins—PTGS2—muscle cancer	6.14e-06	0.000182	CbGpPWpGaD
Erlotinib—ALB—Metabolism of lipids and lipoproteins—PTGS2—muscle cancer	6.11e-06	0.000181	CbGpPWpGaD
Erlotinib—CYP1A2—Metabolism—MED12—muscle cancer	5.99e-06	0.000178	CbGpPWpGaD
Erlotinib—EGFR—Disease—MDM2—muscle cancer	5.85e-06	0.000174	CbGpPWpGaD
Erlotinib—MAP2K5—Signaling Pathways—VEGFA—muscle cancer	5.8e-06	0.000172	CbGpPWpGaD
Erlotinib—EGFR—Disease—PTGS2—muscle cancer	5.64e-06	0.000167	CbGpPWpGaD
Erlotinib—CYP1A2—Metabolism—ENO2—muscle cancer	5.46e-06	0.000162	CbGpPWpGaD
Erlotinib—JAK3—Signaling Pathways—TP53—muscle cancer	5.37e-06	0.00016	CbGpPWpGaD
Erlotinib—ALB—Hemostasis—VEGFA—muscle cancer	5.29e-06	0.000157	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—KIT—muscle cancer	5.2e-06	0.000154	CbGpPWpGaD
Erlotinib—UGT1A1—Metabolism—PTGS2—muscle cancer	5.2e-06	0.000154	CbGpPWpGaD
Erlotinib—CYP1B1—Metabolism—PTGS2—muscle cancer	4.85e-06	0.000144	CbGpPWpGaD
Erlotinib—CYP3A4—Metabolism—MED12—muscle cancer	4.62e-06	0.000137	CbGpPWpGaD
Erlotinib—ABCG2—Metabolism—PTGS2—muscle cancer	4.41e-06	0.000131	CbGpPWpGaD
Erlotinib—MAP2K5—Signaling Pathways—TP53—muscle cancer	4.38e-06	0.00013	CbGpPWpGaD
Erlotinib—CYP1A2—Metabolism of lipids and lipoproteins—PTGS2—muscle cancer	4.27e-06	0.000127	CbGpPWpGaD
Erlotinib—CYP3A4—Metabolism—ENO2—muscle cancer	4.22e-06	0.000125	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—MDM2—muscle cancer	4.1e-06	0.000122	CbGpPWpGaD
Erlotinib—ALB—Hemostasis—TP53—muscle cancer	3.99e-06	0.000119	CbGpPWpGaD
Erlotinib—CYP3A5—Metabolism—PTGS2—muscle cancer	3.16e-06	9.38e-05	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—VEGFA—muscle cancer	3.11e-06	9.24e-05	CbGpPWpGaD
Erlotinib—CYP1A1—Metabolism—PTGS2—muscle cancer	2.98e-06	8.86e-05	CbGpPWpGaD
Erlotinib—CYP2C8—Metabolism—PTGS2—muscle cancer	2.74e-06	8.12e-05	CbGpPWpGaD
Erlotinib—ALB—Metabolism—PTGS2—muscle cancer	2.72e-06	8.08e-05	CbGpPWpGaD
Erlotinib—ABCB1—Metabolism—PTGS2—muscle cancer	2.38e-06	7.08e-05	CbGpPWpGaD
Erlotinib—EGFR—Signaling Pathways—TP53—muscle cancer	2.35e-06	6.98e-05	CbGpPWpGaD
Erlotinib—CYP2D6—Metabolism—PTGS2—muscle cancer	2.25e-06	6.67e-05	CbGpPWpGaD
Erlotinib—CYP1A2—Metabolism—PTGS2—muscle cancer	1.9e-06	5.65e-05	CbGpPWpGaD
Erlotinib—CYP3A4—Metabolism—PTGS2—muscle cancer	1.47e-06	4.36e-05	CbGpPWpGaD
